1st Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$2,700,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 4574/H.R. 8254 (from 116th Congress) Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act (not yet introduced in the 117th Congress) H.R.1319 - 117th Congress (2021-2022):American Rescue Plan Act of 2021 COVID-19 relief packages: Provider Relief Fund and Medicare sequester relief. Federal allocation of COVID-19 vaccine to dialysis providers to directly vaccinate their patients and frontline workers Administrations CMMI Model for Kidney Disease- Delay of voluntary models and ESRD Treatment Choices Model & KCC Model Charitable Premium Assistance Telehealth policies/CMS Waivers Legislation related to the suspension of the Medicare sequester

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Office of the Vice President of the United States; Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 1319 (117th), H.R. 8254 (117th), S. 4574 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.